MVP方案与CAP方案治疗晚期非小细胞肺癌疗效比较  

Comparative study of treatment of the advanced non small cell lung cancer with MVP and CAP chemotherapy protocol

作　　者：陶本春[1] 李本全[1] 李新菊[1] 贾百泉[1] 

机构地区：[1]焦作矿务局中央医院肿瘤科,焦作454150

出　　处：《洛阳医专学报》2000年第1期23-24,共2页Journal of Luoyang Medical College

摘　　要：目的　比较MVP方案与CAP方案对晚期非小细胞肺癌 (NSCLC)的疗效和毒性。方法　分析MVP(丝裂霉素、长春花碱酰胺、顺铂 )方案及CAP(环磷酰胺、阿霉素、顺铂 )方案治疗 6 8例NSCLC的临床资料。结果　MVP组有效率为 40 .6 % ,其中完全缓解 2例 ;CAP组有效率为 2 7.8%。毒性反应主要为骨髓抑制及胃肠道反应。结论由丝裂霉素、长春花碱酰胺、顺铂组成的化疗方案治疗NSCLC的疗效较高 ,且毒性较小 ,患者可以耐受 ,是临床上切实可行的有效方案。Objective To compare the efficacy and toxicity of two different chemotherapy protocols for the advanced non small cell lung cancer (NSCLC). Methods The clinical data of 68 cases with the advanced NSCLC treated with MVP(mitomycinc plus vindesine plus cisplatin) and CAP (cyclophosphamide plus adriamycin plus cisplatin) were analysed. Results The response rate was 40.6% in patients treated with MVP, with 2 cases of CR, 27.8% in those treated with CAP, respectively. The major toxic reactions in the two groups were myelo suppression and the gastroenteric responses. Conclusion MVP is effective and safe chemotherapeutic protocols for the treatment of the advanced NSCLC patients, and to patients, its toxic reaction is weak and telerable.

关 键 词：非小细胞肺癌 MVP方案 CAP方案 治疗 

分 类 号：R734.205[医药卫生—肿瘤]